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Abstract: Familial adenomatous polyposis (FAP) is an autosomal-dominant condition characterized
by the presence of multiple colorectal adenomas, caused by germline variants in the adenomatous
polyposis coli (APC) gene. More than 300 germline variants have been characterized. The detection
of novel variants is important to understand the mechanisms of pathophysiology. We identified a
novel pathogenic germline variant using next-generation sequencing (NGS) in a proband patient.
The variant is a complex rearrangement (c.422+1123_532-577 del ins 423-1933_423-1687 inv) that
generates a complete deletion of exon 5 of the APC gene. To study the variant in other family
members, we designed an endpoint PCR method followed by Sanger sequencing. The variant was
identified in the proband patient’s mother, one daughter, her brother, two cousins, a niece, and a
second nephew. In patients where the variant was identified, we found atypical clinical symptoms,
including mandibular, ovarian, breast, pancreatic, and gastric cancer. Genetic counseling and cancer
prevention strategies were provided for the family. According to the American College of Medical
Genetics (ACMG) guidelines, this novel variant is considered a PVS1 variant (very strong evidence
of pathogenicity), and it can be useful in association with clinical data for early surveillance and
suitable treatment.
Keywords: familial adenomatous polyposis (FAP); adenomatous polyposis coli (APC); pathogenic
germline variant; rearrangement
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1. Introduction
Colorectal cancer (CRC) is a significant cause of morbidity and mortality globally [1].
CRC is the third most commonly diagnosed cancer and the second in mortality, with
1.8 million new cases and almost 861,000 deaths in 2018, according to the GLOBOCAN
database of the World Health Organization (WHO). In Mexico, during 2018, CRC incidence
was 149,000 people, with mortality of 70,841 [2].
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About 85% of all CRC cases are considered sporadic. Hereditary forms of CRC represent up to 15% of all cases and 10% correspond to “familial” cancers, followed by 5% of
hereditary cancer syndromes (HCSs). Hereditary cancer syndromes include nonpolyposis
cancer (HNPCC or Lynch syndrome: ~3–5%) and various polyposis syndromes (~1–2%)
such as familial adenomatous polyposis (FAP), familial juvenile polyposis (JP), MUTHYrelated polyposis, and Peutz–Jeghers syndrome [1]. FAP is an autosomal-dominant condition that affects almost 1 in 5000 people and represents about 1% of all CRC cases [3].
FAP is a precancerous condition that is clinically characterized by the presence of multiple
colorectal adenomas or polyps found in the walls of the large intestine and the rectum [4–6].
Classical FAP usually develops more than 100 polyps, 10 to 100 in its attenuated form and a
profuse form in which there are more than 1000 polyps [7]. The risk of cancer is practically
100% if the polyps are not detected and removed by the time they are 40 years old [1,8].
Prophylactic colectomy, which is the surgical removal or resection of a diseased part of the
colon, has been recommended for these patients [4]. Due to the high risk of developing
colon cancer, 7% of untreated patients will develop colon cancer by age 21, 87% at 45 years,
and 93% by 50 [5].
Symptoms are rare in children and adolescents until the polyps are large and numerous, causing rectal bleeding or even anemia. Other nonspecific symptoms include
constipation or diarrhea, abdominal pain, palpable abdominal masses, and weight loss
in young patients. Extraintestinal manifestations such as osteomas, dental abnormalities,
congenital hypertrophy of the retinal pigment epithelium (CHRPE), desmoid tumors,
and extracolonic cancers may also occur (thyroid, liver, bile ducts, and central nervous
system) [1].
The FAP diagnosis is made considering several factors: phenotype, family history,
medical records, and next-generation sequencing of the adenomatous polyposis coli (APC)
gene. This inherited syndrome is due to germline variants in the APC gene (OMIM
175100) [4], which is a tumor suppressor gene [9] located on the long arm of chromosome
5 in band q21. This gene contains 21 exons within a 98 kb locus [10]. The APC gene
spans a region of 138,742 bp (NC_000005) [1], and the coding region contains 15 exons
in an 8535 nucleotide region encoding a 2843 amino acid multidomain protein with a
molecular weight of 310 kDa [9,11]. The largest exon is exon 15, with a remarkable
6579 bp uninterrupted open reading frame, comprising more than 75% of this gene’s
coding sequence [10].
The APC protein plays an essential role in the cell cycle, motility, adhesion, and signaling. It is often referred to as a multitasking protein, and the disruption of its interactions
can lead to APC’s inability to perform these functions, thereby contributing to tumor formation. APC’s primary functions are downregulation of the Wnt pathway (via β-catenin),
modulation of cell adhesion/migration, and chromosomal stability maintenance [10].
Based on information from the Leiden Open Variation Database, 1801 unique allelic
variants of the APC gene are included (information retrieved on 01/28/2021) [12], and
more than 90% of variants produce a truncated protein as a result of a stop codon, especially
at the C-terminal domain [10]. The most common variant occurring in approximately 10%
of patients with FAP is a deletion at codon 1309 (exon 15); another common variant is
a deletion at codon 1061 (exon 15), occurring in 5% of patients [1]. Deletions in codon
1309 (exon 15) have been identified in patients with no family history, suggesting that they
may also arise de novo. Germline variants can predict the phenotype due to its location
within the APC gene [10,13]. A phenotype of multiple polyps (more than 5000) is predicted
when the variant arises between codon 1249 and codon 1330 of exon 15. The profuse FAP
phenotype involved codon 232 of exon 7 and codons 805, 1062, 1104, and 1309 of exon
15. Variants in codon 1309 correlate with cancer aggressiveness ([13]), whereas variants
upstream or downstream of this region result in a phenotype of fewer than 1000 polyps [12].
Attenuated FAP (AFAP) is caused by variants at codons 78 (exon 3) to 163 (exon 4) at the 50
end. This disease is characterized by the development of very few polyps (less than 100).
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Similarly, germline variants in exon 15 are also associated with an attenuated phenotype [13]. Additionally, the AFAP phenotype has been correlated with variants in three
regions of APC: at the 50 end (the first five exons), in the alternatively spliced region of exon
9, or at the 30 end (after codon 1580) [14]. Germline variants between codons 1395 and 1560
(exon 15) have also been associated with desmoid tumors and mandibular osteomas [10].
There is a correlation between the variants’ site and the clinical phenotype; however, interand intrafamilial variability has been reported [15]. An increasing number of new variant patterns have been reported for some monogenic disorders, including FAP [16]. The
identification of new variants has led to the characterization of hereditary syndromes;
however, there are still rare variants beyond the classical clinical spectrum. Therefore, it is
an obligation of all investigators to describe all novel variants to fulfill these clinical gaps.
This study presents a Mexican family’s molecular analysis in which FAP is due to a
novel germline variant in the APC gene. Once we found the variant in the proband by nextgeneration sequencing (NGS), we developed a low-cost endpoint PCR method followed
by Sanger sequencing to detect the other family members’ germline variant. Herein we
describe the family’s clinical history, the design of a molecular detection method, and the
identification of carriers.
2. Materials and Methods
2.1. Approval from the Scientific and Ethics Committees
The study was conducted in the Centro Universitario Contra el Cáncer (CUCC), at
the CUCC Early Cancer Detection Clinic (CECIL), in accordance with the Declaration of
Helsinki. The Institutional Ethics Committee approved the protocol of the University
Hospital (Registration No.: ON18-00015). All patients were invited to participate in the
research project, an interview was performed, and once the patients agreed to participate,
they signed informed consent. Afterwards, clinical and epidemiological information was
collected, and blood samples were withdrawn.
2.2. Case Presentation
The proband patient was a 49-year-old healthy woman who attended the CECIL consultation because of a family history of cancer; she is the first child of nonconsanguineous
parents. The clinical diagnosis was based on the patient’s family history: a brother with
mandibular cancer at 44, a cousin with colon polyps at 44, the mother had ovarian cancer
at 62, a maternal aunt deceased by pancreatic cancer at 73, grandfather deceased by colon
cancer at 82, great uncle with colon cancer at 80, cousin aunt with breast cancer at 40, and
cousin aunt deceased by gastric cancer at 59. Additionally, two nieces have glycogenosis
type I.
As a proband patient’s pathological clinical history, she had a hernioplasty at the age
of 45, no prescribed medications, menarche at 12, irregular menstruation, was sexually
active since age 29, had Gravida 2 times, and had 2 term pregnancies with normal vaginal
delivery. Her previous cancer prevention studies were a Papanicolau test (normal) and
a mammography (BIRADS 3). She met the clinical criteria for HCS and received genetic
counseling. After the genetic consultation, she was diagnosed with probable Lynch syndrome, and the clinical team recommended a colonoscopy. She returned four months later
with a colonoscopy finding of less than 10 adenomatous polyps, all removed and analyzed
without malignancy. Additionally, she shared new familial information: she informed us
that her brother developed an oral cavity epidermoid carcinoma, and her maternal aunt developed multiple adenomatous polyps in the colon (>10 polyps), duodenum, and stomach
(<10 polyps) at the age of 64 and underwent total colectomy because of the polyposis; some
of the polyps that were analyzed revealing mismatch microsatellite repair (MMR) stability.
With the new data, the diagnosis changed to probable familial polyposis syndromes: FAP
or MUTYH-related.
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2.3. Proband Patient NGS Study
Buccal swab samples were collected from the proband patient. Genetic testing with a
30-gene NGS panel (Onco Life Test® ) from Life in Genomics® (Mexico City, Mexico) was
realized. The panel includes 30 genes for breast and ovarian cancer syndrome (HBOC),
hereditary nonpolyposis colon cancer (HNPCC), Lynch syndrome, FAP, Cowden syndrome,
and Peutz–Jeghers syndrome, as well as for prostate, stomach, pancreas, and fallopian
tube cancers. A pathological variant in the APC gene (c.422 + 1123_532-577 del ins 4231933_423-1687 inv) was found. The novel pathogenic variant was not previously reported
in the ClinVar database from NCBI. This variant results in a complete deletion of exon 5,
keeping the splicing sites intact. Once the variant was identified in the proband patient, a
low-cost endpoint PCR–Sanger sequencing method was designed to analyze the samples
from 10 relatives.
2.4. DNA Extraction and Quantification
Peripheral blood samples (5 mL) from the proband patient and her relatives were
collected by venipuncture. Samples were centrifuged at 1850× g for 10 min at room
temperature. Genomic DNA was isolated from leukocytes using the QIAamp DNA Blood
Midi kit (QIAGEN, Hilden, Germany) following the manufacturer’s recommendations.
DNA was quantified by measuring the optical density (OD) at 260 nm using the QIAxpert UV/Vis spectrophotometer (QIAGEN, Hilden, Germany). The ratio OD260/OD280
determined DNA purity; values between 1.8 and 2 were considered pure. The genomic
DNA was stored at −80 ◦ C until use.
2.5. Primer Design and PCR
Since we were unable to obtain the NGS reference sequence, we constructed the
sequence of the mutated region based on the variant reported by Life in Genomics®
(c.422 + 1123_532-577 del ins 423-1933_423-1687 inv). Oligo Primer analysis software v7 by
Molecular Biology Insights, Inc. (Cascade, CO, USA) [16] was used to design the specific
primers for each APC sequence (native and variant). We developed a pair of primers to
amplify the variant APC allele, the intronic regions that flank the inverted/deleted fragment
(the variant sequence generated by the rearrangement). The primers are the following:
forward 50 -GCGATTCTTCTGCTTCAGTC-30 , reverse 50 -ACACTTATTTGCCAAAGTCAC30 (amplification fragment of 981 bp). To amplify the wild-type APC allele, we designed
a pair of primers that amplify a region of exon 5 and an underlying 30 intronic region:
forward 50 -TGGTATTACGCTCAACTTC-30 and reverse 50 -CAAAACAAACCAGCTTAG-30
(amplification fragment of 546 bp) (Figure 1).
2.6. Native and Variant Regions PCR
The PCR was performed in a total volume of 50 µL using 100 ng of genomic DNA,
25 µL of GoTaq® Colorless Master mix 2X from Promega (Fitchburg, WI, USA) and 0.2 mM
of each primer. The PCR reaction was carried out in a SimpliAmp™ 96-well Thermal Cycler
(Thermo Fisher Scientific, Waltham, MA, USA). The amplification programs used consisted
of an initial hold at 95 ◦ C for 5 min, followed by 30 cycles, each including incubations at
95 ◦ C for 1 min. The alignment temperature for wild-type APC was 51 ◦ C for 1 min, and the
APC variant was 61.5 ◦ C for 1 min and 72 ◦ C for 1 min. Finally, an elongation step at 72 ◦ C
for 7 min was performed. PCR’s amplification products were visualized on 2% agarose
gels stained with SYBR™ Safe DNA Gel Stain from Thermo Fisher Scientific (Waltham,
MA, USA) under UV light.
2.7. Sanger Sequencing
To validate the method, we verified all the amplified products’ sequences by the
Sanger sequencing method. The PCR products were purified with Wizard® SV Gel and
PCR Clean-Up System from Promega (Fitchburg, WI, USA) following the manufacturer’s
instructions. The PCR products were subsequently subjected to sequencing with BigDye
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terminator v1.1 cycle sequencing reagents (Applied Biosystems, Foster City, CA, USA),
purified with BigDye XTerminator™ purification kit (Applied Biosystems, Foster City,
5 of 11
CA, USA) according to the manufacturer’s recommendations, and analyzed on an ABI
3130 genetic analyzer (Applied Biosystems, Foster City, CA, USA).
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We charted a pedigree of the family (Figure 2A) of four generations with a total of
30 people. The pedigree included two patients with colon cancer, the proband’s maternal
grandfather (I-3) and great uncle (I-5); one patient with ovarian cancer, the proband’s
mother (II-5); one patient with pancreatic cancer, the proband’s aunt (II-6); one patient
with colon, duodenal, and gastric polyposis (>10 polyps), the proband’s uncle (II-7); one
patient with breast cancer, the proband’s aunt (II-10); one patient with gastric cancer, the
proband’s aunt (II-11); three patients with colon polyposis, the proband patient (III-4) and
two maternal cousins (III-7 and 9); one patient with oral cavity epidermoid carcinoma and
7 of 11
colon polyposis (III-5), the proband’s brother; and two patients with type
I glycogenosis,
the proband’s nieces (IV-6 and 7).

Figure 2. Detection of the APC variant in the family. (A) Pedigree of the family. Pedigree of the

Figure 2. Detection of the APC variant in the family. (A) Pedigree of the family. Pedigree of the
family carrying the novel APC variant (c.422+1123_532-577 del ins 423-1933_423-1687inv) is shown.
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Due to the proband patient’s interest in confirming the diagnosis in other family
members and their socioeconomic status, using NGS was not an option. Therefore, we
designed a method to detect the variant based on endpoint PCR and Sanger sequencing. We
assembled the mutated allele sequence manually based on the APC gene sequence reported
by the NCBI database (NG_008481.4 RefSeqGene). To create the variant allele, we relied
on the APC gene sequence published in the GenBank database (Gene ID: 324, Ensembl:
ENSG00000134982 MIM: 611731). From the 30 end of exon 4 of the APC gene (nucleotide
422), we counted upstream 1123 nucleotides, being the a-end of the “a-b” fragment shown
in Figure 1. Later at the 50 end of exon 6 of the APC gene (nucleotide 532), 577 nucleotides
were counted downstream; this was the b-end of the fragment. The “a-b” fragment was
deleted entirely. For fragment “c,” from the 50 end of exon 5 of the APC gene (nucleotide
423), we counted 1933 nucleotides upstream with this position being the 50 end of fragment
“c.” We then counted 1687 nucleotides upstream of the 50 end of exon 5 of the APC gene
(nucleotide 423); this is the 30 end of fragment “c.” We inverted this fragment and pasted it
to the APC gene sequence to create the variant allele reference sequence (Figure 1).
We performed an endpoint PCR analysis using the primer sets designed for each one
(native and variant) to amplify the APC alleles. First, we standardized the PCR reaction
using the sample from the index patient as a positive control. As a negative control, we
used the sample from a healthy individual not related to the family (data not shown). Some
of the ten members of the family analyzed were included in Figure 2B. We observed a single
band of 546 bp for wild-type homozygous patients, and for the mutated heterozygous
patients, we predicted and observed two bands, a 981 bp band and a 546 bp band (Figure
8 of 11
2B). First- and second-degree relatives were analyzed; thus, ten family members were
analyzed for the APC variant by PCR assay (indicated by the letter E in Figure 2A; the plus
or minus sign indicates the presence or absence of this variant).
The proband patient’s genetic counseling suggested total colectomy as a cancer preWe confirmed the variant in the proband (III-4) and the family members by the
vention strategy. A colonoscopy was performed on her brother, who was a carrier of the
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4. Discussion
Based on information from the Leiden Open Variation Database (LOVD) database,
1801 unique allelic variants of the APC gene are included in the database (information
retrieved on 01/28/2021) [12]. These variants are heterogeneous and are associated with
colon polyposis in the case of being pathogenic or likely pathogenic. Still, there are also
variants of uncertain significance (VUS) and likely benign ones that do not affect polyp
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The proband patient’s genetic counseling suggested total colectomy as a cancer prevention strategy. A colonoscopy was performed on her brother, who was a carrier of the
variant. More than 100 polyps were found in the colon, and he decided to undergo a total
colectomy. The niece that carries the variant in APC also has confirmed glycogenosis (homozygous pathogenic variant G6PC c.379_380TA/ c.379_380TA), so long-term follow-up is
under a multidisciplinary team.
4. Discussion
Based on information from the Leiden Open Variation Database (LOVD) database,
1801 unique allelic variants of the APC gene are included in the database (information
retrieved on 01/28/2021) [12]. These variants are heterogeneous and are associated with
colon polyposis in the case of being pathogenic or likely pathogenic. Still, there are
also variants of uncertain significance (VUS) and likely benign ones that do not affect
polyp development. According to this classification, among the pathogenic variants,
most are frameshift variants and nonsense variants, with a few larger deletions or splice
variants [15,17,18]. In a review of 431 cases of the Mayo Clinic, 85% of cases were either
frameshift or nonsense, and only 6% were deletions [17]. In one Brazilian cohort, most
of the patients with more than 1000 polyps had APC gene deletion in 42% and nonsense
mutations in 28.5%. Additionally, in patients with less than 100 polyps, 50% was due to
missense mutations [14]. The majority of these variants lead to premature truncation of
the APC protein. Most of the germline variants cause loss of the b-catenin level regulating
domain, axin-binding domain, C-terminus microtubule, and EB1-binding domains [19].
Regarding the position, 60% of all variants in APC fall in the 50 portion of the gene [18,20].
According to the APC variant database, the 5 bp deletion (c.3927-c.3931 delAAAGA),
known as the codon 1309 (exon 15) termination variant, is the most common germline
variant detected [21]. The 1309 variant is associated with the classic form of FAP with more
than 100 polyps in the colon and early colorectal cancer. Variants between codons 1250 to
1464 (exon 15) are associated with profuse polyposis, the most severe form of FAP. Variants
spanning exons 1–5, exon 9, the 30 region of exon 15, and large interstitial 5q deletions are
associated with an attenuated form of FAP (from 10 to 100 polyps) [21].
FAP signs include colonic polyps and extracolonic manifestations, and these are more
frequent between codons 976 to 1067, followed by 1310 to 2011 (this region comprises
exon 15). Variants between codons 543 (exon 12) and 1309 (exon 15) are associated with
congenital hypertrophy of retinal pigment epithelium (CHRPE), whereas variants between
codons 1310 to 2011 have a six-fold risk of developing desmoid tumors compared to codons
159 (exon 4) to 495 (exon 11). Duodenal adenomas, which are the second most frequent
in which polyps develop in FAP, are usually associated with variants between codons 279
(exon 7) and 1309 (exon 15) but can have a three to four times greater chance of appearing if
the variants are between codons 976 and 1067 (exon 15) [22,23]. Another series reported that
the most common extracolonic manifestations were upper gastrointestinal polyps (79%)
and desmoid tumors (57%); in the latter, the variants were located between codons 1444 to
2843 [14]. In a cohort of South Asian families, 45% presented extracolonic manifestations,
the most common was CHRPE in 23.3% and desmoid tumors in 21.6%, with variants in
codons 1483 and 1228, respectively [24].
As seen before, depending on the gene’s site and the type of variant, severity can vary;
however, it also depends on inter- and intrafamilial variability. These show us that the
molecular mechanism that unveils the genotype–phenotype correlation is yet to be fully
understood [15,18].
It is interesting to analyze the variant found in this family (c.422 + 1123_532-577 del
ins 423-1933_423-1687 inv) because it was not previously reported, and it does not fall in
the most frequent type of variant according to the Mayo Clinic Registry. The variant is a
complex rearrangement of various gene sections involving a deletion typically associated
with attenuated phenotype and one insertion and one inversion. Based on the complex
rearrangement of this variant and according to the criteria for classifying pathogenic
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variants of the ACMG standards and guidelines, the evidence of pathogenicity is robust
(PVS1) [25]. PVS1 variants include null variant (nonsense, frameshift, canonical +/−1 or
two splice sites, initiation codon, single or multiexon deletion) in a gene where the loss of
function is a known mechanism of disease [25,26].
Knowing the molecular mechanisms of the genotype–phenotype is still a challenge;
however, despite the high variability in symptoms observed in this family, clinical data
can help us classify this as a novel pathogenic variant (PVS1 variant). The age of onset
of polyps and carcinomas is generally around the fifth decade of life. Regarding the
numbers of polyps, we saw high variability with some of the patients with scarce polyps.
This evidence supports that the variant could be associated with an attenuated form of
FAP. However, as previously mentioned, there is conflicting evidence in the genotype–
phenotype and variable phenotype expression in this disease. There are contradictions in
the literature against the sole use of genotype in making clinical decisions. The studies of
FAP families are still limited and are noticeable for their contradictory findings. Multiple
studies note intra- and interfamily variation in the FAP phenotype in patients carrying
the same mutation [19]. Therefore, functional analysis tests are required to determine this
germ variant’s mechanism in the APC gene. Another interesting finding is the different
neoplasms in the family members that carry the variant. There are several reports of
double heterozygous families and individuals caring variants in genes related to HCS
such as APC/MSH2 in juvenile-onset of colorectal cancer [27], BRCA1/2 in the Ashkenazy
Jewish population with breast cancer [28], APC/MLH1 in multiple jejunum cancer [29],
and APC/BRCA1 in an Italian family with profuse FAP. This last one is very similar to
our case, so the NGS panel test in the mother of the proband (with ovarian cancer) could
lead us to a better understanding of this case [30]. Because of this, the management of the
family should include screening for other types of cancer. Since there is an atypical tumor
spectrum, we speculate the presence of another pathogenic variant in some modifier gene
of low penetrance or another unspecified locus.
To date, there are few reports of germline variability of the APC gene in the Mexican
population. Understanding human genomic variation is a central focus of medical and
population genomics.
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